Seeking Alpha

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer ...
Nasdaq

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...
The American Journal of Managed Care

TRITON Study to Target Biomarkers for Patients With Select NSCLC Mutations

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or ...
News Medical

Dual immunotherapy plus chemotherapy shows promise for specific lung cancer patients

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...